CureVac N.V.

NasdaqGM:CVAC 株式レポート

時価総額:US$619.1m

CureVac 過去の業績

過去 基準チェック /06

CureVac's earnings have been declining at an average annual rate of -12.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 16.5% per year.

主要情報

-12.8%

収益成長率

98.9%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率-16.5%
株主資本利益率-73.9%
ネット・マージン-422.8%
前回の決算情報30 Jun 2024

最近の業績更新

Recent updates

CureVac: Back To Square One

Oct 08

CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk

Sep 16
CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price

Aug 03
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price

We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely

Jul 05
We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely

CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas

Jul 04

Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

Jun 01
Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

Mar 20
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

CureVac: No Momentum In Sight

Mar 08

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Aug 26
What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 14
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

May 01
Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Apr 29
Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Jan 08
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

CureVac BV reports Q2 results

Aug 18

CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine

Jul 05

Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

May 29
Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

May 02
Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

Oct 28
A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

CureVac: Wait For Concrete News Before Investing

Sep 01

CureVac plunges as COVID-19 vaccine candidate indicates below par efficacy

Jun 16

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

Jun 13
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

CureVac tumbles on potential delay for European decision on its COVID-19 shot

Jun 08

CureVac: The Moment Of Truth Arrives

Jun 01

CureVac BV reports Q1 results

May 26

CureVac Could Soon Join The Fight Against COVID-19

May 10

CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability

May 02
CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability

収支内訳

CureVac の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGM:CVAC 収益、費用、利益 ( )EUR Millions
日付収益収益G+A経費研究開発費
30 Jun 2466-27885116
31 Mar 2459-27392119
31 Dec 2354-26096116
30 Sep 2343-30295110
30 Jun 2338-30110395
31 Mar 2350-29110676
31 Dec 2267-24910763
30 Sep 2297-122100566
30 Jun 22115-219103602
31 Mar 22117-313105722
31 Dec 21103-412102816
30 Sep 2168-468102322
30 Jun 2144-36181308
31 Mar 2156-21964208
31 Dec 2049-12954114
30 Sep 2050-1075689
31 Mar 2017-1025643
31 Dec 1917-1005143
31 Dec 1813-712642

質の高い収益: CVAC is currently unprofitable.

利益率の向上: CVAC is currently unprofitable.


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: CVAC is unprofitable, and losses have increased over the past 5 years at a rate of 12.8% per year.

成長の加速: Unable to compare CVAC's earnings growth over the past year to its 5-year average as it is currently unprofitable

収益対業界: CVAC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


株主資本利益率

高いROE: CVAC has a negative Return on Equity (-73.95%), as it is currently unprofitable.


総資産利益率


使用総資本利益率


過去の好業績企業の発掘